ArticleBMC cardiovascular disorders2025
Protective effects of combined eptifibatide and ticagrelor in patients with unstable angina undergoing percutaneous coronary intervention: a single-center experience.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundWe evaluated the safety and effectiveness of combined eptifibatide and ticagrelor in patients with unstable angina pectoris undergoing percutaneous coronary intervention (PCI).
methodsPatients with unstable angina pectoris who underwent PCI from January 2019 to December 2020 were included. All patients were treated with aspirin and ticagrelor as dual antiplatelet therapy and divided into two groups: the eptifibatide + ticagrelor group (180 µg/kg bolus plus 1 µg/kg/min continuous intravenous eptifibatide infusion after PCI for 24 h [n = 152]) and the ticagrelor group (without eptifibatide infusion [n = 152]). Thromboelastography and light transmission aggregometry were used to measure the adenosine diphosphate-induced platelet aggregation rate (PAR). High sensitivity troponin T (hs-TnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), high-sensitivity C-reactive protein (hs-CRP), and heart-type fatty acid-binding protein (h-FABP) were measured. In-hospital and 12-month major adverse cardiovascular events (MACEs) and bleeding events were evaluated.
resultsThe PAR significantly declined at 1, 12, and 24 h after continuous intravenous eptifibatide and returned to the pretreatment level 24 h after discontinuation. All patients in the eptifibatide + ticagrelor group achieved a PAR < 10%. The percentage of patients with a PAR < 10% was significantly higher than in the ticagrelor group (P < 0.001). The increases in hs-TnT (P < 0.001), NT-proBNP (P < 0.05), and h-FABP (P < 0.05) were less pronounced. The eptifibatide + ticagrelor group exhibited lower rates of in-hospital and 12-month myocardial infarction (MI) and in-hospital MACEs (P < 0.05). The rate of bleeding events was not significantly different.
conclusionEptifibatide rapidly reduced the PAR in patients with unstable angina pectoris and reduced the rates of MI, in-hospital MACEs, and 12-month MI, without increasing bleeding events. The combined use of eptifibatide and ticagrelor was safe and effective.
trial registrationThe registry was registered in the Chinese Clinical Trial Registry (ChiCTR2500096895). The date of registration was 2025-02-08, and it was "Retrospectively registered".
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.